Skip to main content

Acumen Pharmaceuticals, Inc.

corporate_fare Company Profile

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ·Life Sciences·CIK 0001576885

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a disease-modifying approach for Alzheimer's disease (AD). AD is a progressive neurodegenerative disease affecting approximately seven million people in the United States and 55 million worldwide. In 2022, it was the sixth-leading cause of death for individuals aged 65 and older in the United States. Without effective treatments, the U.S. patient population is projected to reach 13 million by 2050, with healthcare costs nearing $1 trillion. The company's scientific founders conducted pioneering research on soluble amyloid-beta oligomers (AßOs), which are distinct from Aß monomers and amyloid plaques and are increasingly recognized as a primary toxin in AD pathology. Acumen Pharmaceuticals is currently advancing sabirnetug (ACU193), a targeted immunotherapy drug candidate, in its Phase 2 ALTITUDE-AD clinical trial. Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2) monoclonal antibody (mAb) designed to selectively target AßOs. It has shown functional and protective effects in in vitro assays and demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. It also demonstrated safety and pharmacologic activity in human AD patients during the Phase 1 INTERCEPT-AD clinical trial, with results announced in July 2023.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for ABOS spans 8-K, S-3, 10-Q, DEF 14A.

Recent high-impact activity:

  • Acumen Cuts 90% of Staff and Repays $23.3M Loan After Sabirnetug Failure
  • Lead Alzheimer's Drug Fails Phase 2 Trial; Company Halts Development and Explores Strategic Options
  • Acumen Files $500M Shelf With Cash Running to Early 2027 and Going-Concern Doubt
  • Acumen Sets November 2026 ALTITUDE-AD Readout With $78.6M Cash Into Early 2027
  • Q3 Loss Narrower Than Expected at $25.8M Operating, $0.35 EPS

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$121.33M
Diluted EPS
-$2.00
Op. Cash Flow
-$115.54M
Free Cash Flow
-$115.63M
Operating Income
-$123.83M
Cash & Equivalents
$53.99M
Total Debt
$31.16M
Debt / Equity
0.44×
Shares Outstanding
60.58M sh
Source: 10-K · filed 2026-03-26 · accession 0001628280-26-021413

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 4,556,267 shares in ABOS as of the October 30, 2026 settlement, a 47.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 63.1% of ABOS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,556,267 shares as of October 30, 2026
Change vs prior period▲ 47.4%
Days to cover1.00 at avg daily volume of 6,864,487
Daily short volume (FINRA facilities)63.1% of 1,354,140 shares on November 19, 2026
5-day average short volume60.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ABOS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-26.

1 shelf registration

Shelf Registers Up to $500 Million · Cash Runs Out in Early 2027

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.1989 +2.31% today
52-week range · as of 2026-11-05 $0.1911 – $3.6
Market cap
$13.98M
Volume
2.2M (0.4× avg)
3-mo avg 5.2M
Live data · 2026-11-20 12:57 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed ABOS - Latest Insights

ABOS
Nov 05, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2143
Real-time Price: $0.1989 info
Change: -$0.0154 (-7%) info
Market Cap: $13.981M info
ABOS
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $1.40
Real-time Price: $0.1989 info
Change: -$1.20 (-86%) info
Market Cap: $13.981M info
ABOS
Oct 26, 2026, 4:21 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $0.1989 info
Change: -$2.10 (-91%) info
Market Cap: $13.981M info
ABOS
Oct 26, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $0.1989 info
Change: -$1.82 (-90%) info
Market Cap: $13.981M info
ABOS
Oct 26, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.04
Real-time Price: $0.1989 info
Change: -$1.84 (-90%) info
Market Cap: $13.981M info
ABOS
Sep 16, 2026, 9:26 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.95
Real-time Price: $0.1989 info
Change: -$2.75 (-93%) info
Market Cap: $13.981M info
ABOS
Aug 12, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.51
Real-time Price: $0.1989 info
Change: -$2.31 (-92%) info
Market Cap: $13.981M info
ABOS
Aug 12, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.46
Real-time Price: $0.1989 info
Change: -$2.26 (-92%) info
Market Cap: $13.981M info
ABOS
Aug 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.46
Real-time Price: $0.1989 info
Change: -$2.26 (-92%) info
Market Cap: $13.981M info
ABOS
Jun 16, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.36
Real-time Price: $0.1989 info
Change: -$2.16 (-92%) info
Market Cap: $13.981M info
ABOS
Jun 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $0.1989 info
Change: -$2.19 (-92%) info
Market Cap: $13.981M info
ABOS
May 12, 2026, 5:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.48
Real-time Price: $0.1989 info
Change: -$2.28 (-92%) info
Market Cap: $13.981M info
ABOS
May 12, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.57
Real-time Price: $0.1989 info
Change: -$2.37 (-92%) info
Market Cap: $13.981M info
ABOS
Apr 23, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.67
Real-time Price: $0.1989 info
Change: -$2.47 (-93%) info
Market Cap: $13.981M info
ABOS
Apr 01, 2026, 5:15 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $2.55
Real-time Price: $0.1989 info
Change: -$2.35 (-92%) info
Market Cap: $13.981M info
ABOS
Mar 26, 2026, 4:29 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $2.43
Real-time Price: $0.1989 info
Change: -$2.23 (-92%) info
Market Cap: $13.981M info
ABOS
Mar 26, 2026, 4:06 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.55
Real-time Price: $0.1989 info
Change: -$2.35 (-92%) info
Market Cap: $13.981M info
ABOS
Mar 26, 2026, 7:06 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $2.66
Real-time Price: $0.1989 info
Change: -$2.46 (-93%) info
Market Cap: $13.981M info
ABOS
Mar 26, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.66
Real-time Price: $0.1989 info
Change: -$2.46 (-93%) info
Market Cap: $13.981M info
ABOS
Mar 17, 2026, 4:33 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $3.11
Real-time Price: $0.1989 info
Change: -$2.91 (-94%) info
Market Cap: $13.981M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets